ArticlePLoS neglected tropical diseases2014
Biomarkers in Trypanosoma cruzi-infected and uninfected individuals with varying severity of cardiomyopathy in Santa Cruz, Bolivia.
Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis.The American journal of tropical medicine and hygiene · 2023Pooled it
- Effects of pentoxifylline in patients with chronic Chagas cardiomyopathy: A randomized, double-blind, controlled pilot trial.PLoS neglected tropical diseases · 2025Trial
- Genomic diversity of Trypanosoma cruzi clinical isolates: a retrospective analysis.The Lancet. Microbe · 2026Article
- A Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions.The Journal of clinical investigation · 2026Article
- ClinicalbioRxiv : the preprint server for biology · 2025Article
- Profile of soluble cell adhesion molecules as potential biomarkers in the cardiac stages of chronic Chagas disease.Frontiers in immunology · 2025Article
- Cardiovascular outcomes of chagas-induced non-ischemic cardiomyopathy versus other nonischemic cardiomyopathies: a regression matched national cohort analysis.American journal of cardiovascular disease · 2025Article
- Persistent Biofluid Small-Molecule Alterations Induced byACS infectious diseases · 2023Article
- Persistent biofluid small molecule alterations induced bybioRxiv : the preprint server for biology · 2023Article
- Cytokine Networks as Targets for Preventing and Controlling Chagas Heart Disease.Pathogens (Basel, Switzerland) · 2023Review
- Prognosis of chronic Chagas heart disease and other pending clinical challenges.Memorias do Instituto Oswaldo Cruz · 2022Article
- Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death.Pathogens (Basel, Switzerland) · 2021Review
- Biomarkers assessment in patients with Chagas disease and systemic arterial hypertension.Parasitology research · 2021Article
- Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Article
- Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy.PloS one · 2021Article
- MMP-2 and MMP-9 plasma levels are potential biomarkers for indeterminate and cardiac clinical forms progression in chronic Chagas disease.Scientific reports · 2019Article
- Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic Chagas Cardiomyopathy.Disease markers · 2019Article
- Severity of Chagasic Cardiomyopathy Is Associated With Response to a Novel Rapid Diagnostic Test for Trypanosoma cruzi TcII/V/VI.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Article
- Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.International journal of cardiology · 2015Article
Corrections and comments
- Erratum issuedQ, Rose [corrected to Do, Rose Q]
Authors and funding
17 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundTwenty to thirty percent of persons with Trypanosoma cruzi infection eventually develop cardiomyopathy. If an early indicator were to be identified and validated in longitudinal studies, this could enable treatment to be prioritized for those at highest risk. We evaluated cardiac and extracellular matrix remodeling markers across cardiac stages in T. cruzi infected (Tc+) and uninfected (Tc-) individuals.
methodsParticipants were recruited in a public hospital in Santa Cruz, Bolivia and assigned cardiac severity stages by electrocardiogram and echocardiogram. BNP, NTproBNP, CKMB, troponin I, MMP-2, MMP-9, TIMP-1, TIMP-2, TGFb1, and TGFb2 were measured in specimens from 265 individuals using multiplex bead systems. Biomarker levels were compared between Tc+ and Tc- groups, and across cardiac stages. Receivers operating characteristic (ROC) curves were created; for markers with area under curve>0.60, logistic regression was performed.
resultsAnalyses stratified by cardiac stage showed no significant differences in biomarker levels by Tc infection status. Among Tc+ individuals, those with cardiac insufficiency had higher levels of BNP, NTproBNP, troponin I, MMP-2, TIMP-1, and TIMP-2 than those with normal ejection fraction and left ventricular diameter. No individual marker distinguished between the two earliest Tc+ stages, but in ROC-based analyses, MMP-2/MMP-9 ratio was significantly higher in those with than those without ECG abnormalities.
conclusionsBNP, NTproBNP, troponin I, MMP-2, TIMP-1, and TIMP-2 levels rose with increasing severity stage but did not distinguish between Chagas cardiomyopathy and other cardiomyopathies. Among Tc+ individuals without cardiac insufficiency, only the MMP-2/MMP-9 ratio differed between those with and without ECG changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.